Conditions: Macular Degeneration
Keywords: Alprostadil prostaglandin E1 Prostavasin® macular degeneration
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 37
Healthy volunteers: no

Brief summary:
Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration

Detailed description:
Results of the planned interim analysis indicated that the number of originally planned patients were not sufficient to reach statistical significance in the primary end point. Instead of increasing the sample size accordingly, it was decided to terminate the study and plan future proceedings based on a careful analysis of the unblinded results.

Arms:
arm 1: Alprostadil arm 2: Placebo

Interventions: intervention 1: Alprostadil (prostaglandin E1) intervention 2: Placebo
Intervention descriptions: intervention 1: Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days. intervention 2: Placebo/d i.v. for 15 days

Protocol document: